Protein Therapeutics

Vibha Jawa, Leslie P. Cousens, Michel Awwad, Eric Wakshull, Harald Kropshofer, Anne S. De Groot, T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clinical Immunology, Volume 149, Issue 3, Part B, December 2013, Pages 534-555, ISSN 1521-6616,

Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol. 2012 Mar;142(3):320-31.

Jawa, V., Cousens, L., & De Groot, A. S. (2013). Immunogenicity of Therapeutic Fusion proteins: Contributory Factors and Clinical Experience. Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges, 75-90.

Scott DW, De Groot AS. Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis. 2010 Jan;69 Suppl 1:i72-76. doi: 10.1136/ard.2009.

Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context.Adv Drug Deliv Rev. 2009 Sep 30;61(11):965-76.

De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 2009 May;131(2):189-201.

De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol. 2008 Oct;8(5):620-6.

De Groot AS, Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel. 2007 May;10(3):332-40

De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007 Nov;28(11):482-90. Epub 2007 Oct 25

Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec M, Weeraratne D, Swanson S, Martin W. Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol. 2007 Jul.